Qualigen Therapeutics (Qualigen Therapeutics) Debt-to-Equity : -0.62 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics Debt-to-Equity?

Qualigen Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.30 Mil. Qualigen Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Qualigen Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-2.10 Mil. Qualigen Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.62.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Qualigen Therapeutics's Debt-to-Equity or its related term are showing as below:

QLGN' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.15 Med: -0.26 Max: 0.19
Current: -0.62

During the past 4 years, the highest Debt-to-Equity Ratio of Qualigen Therapeutics was 0.19. The lowest was -1.15. And the median was -0.26.

QLGN's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs QLGN: -0.62

Qualigen Therapeutics Debt-to-Equity Historical Data

The historical data trend for Qualigen Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics Debt-to-Equity Chart

Qualigen Therapeutics Annual Data

Trend

Mar20

Dec21

Dec22

Dec23

Debt-to-Equity

-1.15

0.10

0.19

-0.62

Qualigen Therapeutics Quarterly Data
	Jun19	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial													0.19	0.62	1.58	-0.51	-0.62

Competitive Comparison of Qualigen Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Qualigen Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qualigen Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's Debt-to-Equity falls into.

Qualigen Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Qualigen Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.299	+	0)	/	-2.104
	=	-0.62

Qualigen Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.299	+	0)	/	-2.104
	=	-0.62

Qualigen Therapeutics (NAS:QLGN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Qualigen Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualigen Therapeutics (Qualigen Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (NAS:QLGN) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

7R9:Germany

Address

2042 Corte del Nogal, Suite B, Carlsbad, CA, USA, 92011

Website

https://www.qualigeninc.com

Qualigen Therapeutics Inc is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases using nanoparticle coating technology. It is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics. The Company has viewed its operations and managed its business in one segment operating mainly within the United States and Israel.

Executives

Michael S. Poirier	director, officer: Chairman, President and CEO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Amy S. Broidrick	director	1440 VALLE GRANDE, ESCONDIDO CA 92025
Kurt H Kruger	director	100 FOXBOROUGH BLVD, SUITE 240, FOXBOROUGH MA 02035
Tariq Arshad	officer: SVP/Chief Medical Officer	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Christopher L. Lotz	officer: Vice President of Finance, CFO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 90211
Emery Sidney W Jr	director	C/O QUALIGEN THERAPEUTICS, INC., 2042 CORTE DEL NOGAL, CARLSBAD CA 92011
Richard A. David	director	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Wajdi Abdul-ahad	officer: VP, R&D, CSO	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Shishir K. Sinha	officer: VP of Operations	2042 CORTE DEL NOGAL, SUITE B, CARLSBAD CA 92011
Sekisui Diagnostics, Llc	10 percent owner	1 WALL STREET, BURLINGTON MA 01803
Matthew E Korenberg	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Noah Doyle	director	C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
John W Beck	officer: Chief Financial Officer	C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Jeffrey S Benjamin	officer: VP of Finance	3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
William M. Merino	director	C/O RITTER PHARMACEUTICALS INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067